Published in Intervirology on November 10, 2016
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine (2007) 2.31
Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis (2002) 2.26
Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One (2008) 2.16
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol (2009) 1.73
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30
Rapid proton-detected NMR assignment for proteins with fast magic angle spinning. J Am Chem Soc (2014) 1.29
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol (2007) 1.25
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
Evidence for arbovirus dissemination conduits from the mosquito (Diptera: Culicidae) midgut. J Med Entomol (2004) 1.09
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol (2009) 1.05
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine (2010) 1.05
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology (2013) 1.02
Vaccination against GIP for the treatment of obesity. PLoS One (2008) 1.01
Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol (2010) 1.01
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol (2005) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol (2002) 1.00
Molecular epidemiology and immunology of hepatitis B virus infection - an update. Intervirology (2002) 0.99
Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines (2008) 0.99
Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol (2009) 0.98
Structural basis of RNA binding discrimination between bacteriophages Qbeta and MS2. Structure (2006) 0.98
Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol (2005) 0.96
Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine (2010) 0.94
Comparison of biomechanical and structural properties between human aortic and pulmonary valve. Eur J Cardiothorac Surg (2004) 0.94
Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol (2010) 0.94
The structure of bacteriophage phiCb5 reveals a role of the RNA genome and metal ions in particle stability and assembly. J Mol Biol (2009) 0.94
Investigating the structural basis of purine specificity in the structures of MS2 coat protein RNA translational operator hairpins. Nucleic Acids Res (2002) 0.94
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol (2005) 0.94
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94
Dynamics of magnetotactic bacteria in a rotating magnetic field. Biophys J (2007) 0.93
Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2009) 0.93
Complete genome sequence of the Enterobacter cancerogenus bacteriophage Enc34. J Virol (2012) 0.92
Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology (2013) 0.92
A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice. PLoS One (2013) 0.92
Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol (2004) 0.92
Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol (2008) 0.91
Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2. Thromb Haemost (2003) 0.91
Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat (2003) 0.91
Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J (2009) 0.90
Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol (2005) 0.90
Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol (2009) 0.90
Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes. Clin Vaccine Immunol (2010) 0.89
Alternative mutations of a positively selected residue elicit gain or loss of functionalities in enzyme evolution. Proc Natl Acad Sci U S A (2006) 0.89
Crystal packing of a bacteriophage MS2 coat protein mutant corresponds to octahedral particles. Protein Sci (2008) 0.89
Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine. Vaccine (2012) 0.89
Recombinant virus-like particles as a carrier of B- and T-cell epitopes of hepatitis C virus (HCV). Vaccine (2006) 0.89
Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines (2012) 0.88